RayKnowChina Research Map
Shortlist

ShanghaiNaval Medical University

Changzheng Hospital

海军军医大学第二附属医院(长征医院)

Listed for 18 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Changzheng Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌3 papers led
  2. Hepatocellular carcinoma肝细胞癌15 papers led1 open trial led
  3. Stomach cancer胃癌17 papers led1 open trial led
  4. Chordoma脊索瘤5 papers led
  5. Osteosarcoma骨肉瘤16 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤4 papers led
  7. Neuroblastoma神经母细胞瘤0 papers led
  8. Ewing sarcoma尤文肉瘤2 papers led
  9. Multiple myeloma多发性骨髓瘤26 papers led2 open trials led
  10. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  11. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  12. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  13. Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
  14. Behçet disease白塞病1 paper led
  15. IgA nephropathyIgA 肾病5 papers led
  16. Osteogenesis imperfecta成骨不全症2 papers led
  17. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  18. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 3 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomicsImaging & AISurgery
Departments in papersRadiology / nuclear medicine
Papers it led3
  1. FOXA3: A Novel Tumor Suppressor in Esophageal Squamous Cell Carcinoma.2025The journal of gene medicine
  2. Potential value of CT-based comprehensive nomogram in predicting occult lymph node metastasis of esophageal squamous cell paralaryngeal nerves: a two-center study.2024Journal of translational medicineFree full text
  3. Transcervical inflatable mediastinoscopic esophagectomy versus thoracoscopic esophagectomy for local early- and intermediate-stage esophageal squamous cell carcinoma: A propensity score-matched analysis.2022Journal of surgical oncologyFree full text
Chinese-language papers (not in the count)1
  1. [Research on the application of combined inflatable mediastinoscopy with laparoscopy guided by the concept of "reduced field and port" in esophageal squamous cell carcinoma].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
More papers found outside PubMed (not counted)10
  1. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  2. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  3. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  4. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  5. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  6. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  7. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  8. Additional file 2 of Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma2022Figsharedataset
  9. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  10. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 15 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
15
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 2220232024: 7720242025: 112025

15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
    Phase
    Early phase 1
    Started
    2024-10
    Registry
    NCT06418659

    Age 18 years to Not stated (registered criteria)

    Led by Changzheng HospitalShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsLocal treatment (ablation, TACE, HAIC)
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicinePathology / laboratory medicine
Papers it led15
  1. Effectiveness of Nursing Care Intervention Among Patients With Hepatocellular Carcinoma Undergoing Surgery: A Systematic Review and Meta-Analysis.2025International journal of nursing practice
  2. DDR1 is a Novel Biomarker and Potential Therapeutic Target for the Combination Treatment of Liver Hepatocellular Carcinoma.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  3. Tripartite motif 8 promotes the progression of hepatocellular carcinoma via mediating ubiquitination of HNF1α.2024Cell death & diseaseFree full text
  4. Profiling of aberrant sialylated N-glycans in hepatocellular carcinoma by liquid chromatography mass spectrometry.2024Clinica chimica acta; international journal of clinical chemistry
  5. Combined RNAi of CTTN and FGF2 Modulates Cell Migration, Invasion and G1/S Transition of Hepatocellular Carcinoma through Ras/ERK Signaling Pathway.2024Current cancer drug targets
  6. Dichotomous roles of ADAR1 in liver hepatocellular carcinoma and kidney renal cell carcinoma: Unraveling the complex tumor microenvironment and prognostic significance.2024International immunopharmacology
  7. Abrogating K458 acetylation enhances hepatocyte nuclear factor 4α (HNF4α)-induced differentiation therapy for hepatocellular carcinoma.2024Journal of digestive diseases
  8. Cathepsin V is correlated with the prognosis and tumor microenvironment in liver cancer.2024Molecular carcinogenesis
  9. Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B.2023Alimentary pharmacology & therapeutics
  10. Role of miRNA-99a-5p in Modulating the Function of Hepatocellular Carcinoma Cells: Bioinformatics Analysis and In Vitro Assay.2023Current cancer drug targets
  11. Influence of Three-Dimensional Visual Reconstruction Technology Combined with Virtual Surgical Planning of CTA Images on Precise Resection of Liver Cancer in Hepatobiliary Surgery.2022Computational and mathematical methods in medicineFree full text
  12. Operator radiation dose during trans-hepatic arterial chemoembolization: different patients' positions via transradial or transfemoral access.2022Diagnostic and interventional radiology (Ankara, Turkey)RCTFree full text
  13. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  14. Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy.2021European journal of pharmacology
  15. Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)1
  1. [Advances of TRIM superfamily proteins in chronic liver disease and hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status3
  1. A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC PatientsRecruitingNCT06418659Lead sponsorEarly phase 1Start 2024-10
  2. A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular CarcinomaCompletedNCT06092112Lead sponsorEarly phase 1Start 2023-10
  3. T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma PatientsTerminatedNCT00057382Study sitePhase 2/Phase 3Start 2003-03

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 17 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
17
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 4420232024: 0020242025: 552025

18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07621484

    Age 18 years to 75 years (registered criteria)

    Led by Changzheng HospitalShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsSurgery
Departments in papersMedical oncologyGastroenterology / hepatology
Papers it led17
  1. Organoid-based single cell sequencing revealed the lineage evolution during docetaxel treatment in gastric cancer.2025Cancer letters
  2. Brucea javanica Seed Oil Emulsion and Shengmai Injections Improve Peripheral Microcirculation in Treatment of Gastric Cancer.2025Chinese journal of integrative medicine
  3. Effect and Mechanism of 6-Gingerol against Precancerous Lesions of Gastric Cancer Based on Network Pharmacology and In Vitro Experiment.2025Combinatorial chemistry & high throughput screening
  4. Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer.2025Frontiers in immunologyFree full text
  5. Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial.2025Nature communicationsFree full text
  6. Tumor- and metastasis-promoting roles of miR-488 inhibition via HULC enhancement and EZH2-mediated p53 repression in gastric cancer.2023Cell biology and toxicology
  7. PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients.2023Clinical genetics
  8. Research progress on the immune microenvironment and immunotherapy in gastric cancer.2023Frontiers in immunologyFree full text
  9. Xiaotan Sanjie decoction normalizes tumor permissive microenvironment in gastric cancer (Review).2023Oncology reports
  10. Long non-coding RNA ncRuPAR regulates gastric cancer cell proliferation and apoptosis via phosphoinositide 3-kinase/protein kinase B signaling.2022International journal of medical sciencesFree full text
  11. Folate Decorated Multifunctional Biodegradable Nanoparticles for Gastric Carcinoma Active Targeting Theranostics.2022International journal of nanomedicineFree full text
  12. Ziyin Huatan Recipe, a Chinese herbal compound, inhibits migration and invasion of gastric cancer by upregulating RUNX3 expression.2022Journal of integrative medicine
  13. UBE3C promotes proliferation and inhibits apoptosis by activating the β-catenin signaling via degradation of AXIN1 in gastric cancer.2021Carcinogenesis
  14. Simultaneous laparoscopic subtotal gastrectomy (Billroth II) and total colectomy with ileorectal anastomosis for synchronous gastric and multifocal colon cancer - a video vignette.2021Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  15. The effects of gastric cancer interstitial fluid on tumors based on traditional Chinese medicine 'phlegm' theory and the investigation on the mechanism through microRNA-21 regulation.2021Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  16. Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis.2021Technology in cancer research & treatmentFree full text
  17. HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma.2021The oncologistFree full text
All its trials on ClinicalTrials.gov, any status6
  1. HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric CancerRecruitingNCT07621484Lead sponsorPhase 2Start 2026-07
  2. Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)Status unknownNCT04278222Lead sponsorPhase 2Start 2020-02
  3. EGFR Monoclonal Antibody for Advanced Gastric CancerStatus unknownNCT04136600Lead sponsorPhase 2Start 2019-07
  4. Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GCStatus unknownNCT04638959Study siteStart 2019-09
  5. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)CompletedNCT03399110Study sitePhase 3Start 2018-01
  6. A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced NeuropathyTerminatedNCT02560740Study siteN/AStart 2016-03

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 5 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 4.8%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

15 hospitals in Shanghai for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Papers it led5
  1. Targeting the tumor immune microenvironment in chordoma: From mechanistic insights to therapeutic breakthroughs.2026Biochimica et biophysica acta. Reviews on cancer
  2. Gross Total Resection of the Entire Cervical Spine Tumor: A Technical Note on Surgical Planning and Design of a Novel 3D-Printed Vertebral Prosthesis for Reconstruction from Skull Base to Thoracic Vertebra.2026World neurosurgery
  3. Ubiquitin-independent pathway regulates the RIT1-MAPK pathway in chordoma progression.2025Cell death & disease
  4. A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib.2024Journal of cancer research and clinical oncology
  5. Early Major Complications After Radical Resection of Primary C2-Involved Upper Cervical Chordoma Through the Combined Anterior Retropharyngeal-Posterior Approach: Incidence and Risk Factors.2021World neurosurgery
Earlier papers (2016–2020)8
  1. Shifting from targeted therapies to personalised treatment in chordoma - Authors' reply.2020The Lancet. Oncology
  2. Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study.2020The Lancet. Oncology
  3. Application of Individualized 3D-Printed Artificial Vertebral Body for Cervicothoracic Reconstruction in a Six-Level Recurrent Chordoma.2020Turkish neurosurgery
  4. Recurrence or neurological loss? Resection mode selection for patients with large sacral chordoma: an analysis of prognostic factors and quality of life.2019Acta neurochirurgica
  5. Prognostic significance of pretreatment plasma D-dimer levels in patients with spinal chordoma: a retrospective cohort study.2019European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  6. Surgical Consideration for Adolescents and Young Adults With Cervical Chordoma.2017Spine
  7. Epidemiological characteristics of primary spinal osseous tumors in Eastern China.2017World journal of surgical oncology
  8. Spine extra-osseous chordoma mimicking neurogenic tumors: report of three cases and review of the literatures.2016World journal of surgical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 16 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
16
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 4420232024: 4420242025: 552025

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Papers it led16
  1. Lactate Activates the HCAR1/β-Arrestin2/PP2A Signaling Axis to Mediate STAT1/2 Dephosphorylation and Drive Osteosarcoma Progression.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  2. Bone-Targeted Fluoropeptide Nanoparticle Inhibits NF-κB Signaling to Treat Osteosarcoma and Tumor-Induced Bone Destruction.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  3. Decoding Osteosarcoma's Lactylation Gene Expression: Insights Into Prognosis, Immune Dynamics, and Treatment.2025Analytical cellular pathology (Amsterdam)
  4. Targeting AKT as a promising strategy for SOX2-positive, chemoresistant osteosarcoma.2025Bone research
  5. The malignant dialogue between cancer-associated fibroblasts and osteosarcoma cells: microenvironment-mediated drug resistance and therapeutic targets.2025Frontiers in immunology
  6. IL-11-Engineered Macrophage Membrane-Coated Reactive Oxygen Species-Responsive Nanoparticles for Targeted Delivery of Doxorubicin to Osteosarcoma.2024ACS applied materials & interfaces
  7. KDELR1 regulates chondrosarcoma drug resistance and malignant behavior through Intergrin-Hippo-YAP1 axis.2024Cell death & disease
  8. New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma.2024Frontiers in immunology
  9. Small Nuclear Ribonucleoprotein Polypeptides B and B1 Promote Osteosarcoma Progression via Activating the Ataxia-Telangiectasia Mutated Signaling Pathway through Ribonucleotide Reductase Subunit M2.2024The American journal of pathology
  10. Deubiquitinase USP13 regulates glycolytic reprogramming and progression in osteosarcoma by stabilizing METTL3/m6A/ATG5 axis.2023International journal of biological sciences
  11. BARX1 promotes osteosarcoma cell proliferation and invasion by regulating HSPA6 expression.2023Journal of orthopaedic surgery and research
  12. Prognostic factors of sarcomas occurring in bone and joint: A SEER based study.2023Medicine
  13. Study on the effect of artificial joint replacement for osteosarcoma.2023Medicine
  14. AMTB, a TRPM8 antagonist, suppresses growth and metastasis of osteosarcoma through repressing the TGFβ signaling pathway.2022Cell death & disease
  15. TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling.2022Redox biology
  16. Identifying the Risk Factors and Estimating the Prognosis in Patients with Pelvis and Spine Ewing Sarcoma: A Population-Based Study.2021Spine
Earlier papers (2016–2020)25
  1. Secondary aneurysmal bone cyst of the spine: Clinicopathological features, surgical modalities and outcomes.2020Clinical neurology and neurosurgery
  2. The CD24+ cell subset promotes invasion and metastasis in human osteosarcoma.2020EBioMedicine
  3. Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma.2020International journal of biological sciences
  4. Long intergenic non-coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo.2020Journal of clinical laboratory analysis
  5. Hypoxia-Inducible Factor 1A Upregulates HMGN5 by Increasing the Expression of GATA1 and Plays a Role in Osteosarcoma Metastasis.2019BioMed research international
  6. The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.2019Biochemical and biophysical research communications
  7. MicroRNA-221 promotes cisplatin resistance in osteosarcoma cells by targeting PPP2R2A.2019Bioscience reports
  8. EWS-FLI1-mediated tenascin-C expression promotes tumour progression by targeting MALAT1 through integrin α5β1-mediated YAP activation in Ewing sarcoma.2019British journal of cancer
  9. GREM1 overexpression inhibits proliferation, migration and angiogenesis of osteosarcoma.2019Experimental cell research
  10. Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy.2019International journal of nanomedicine
  11. Prognostic Factors for Patients With Undifferentiated High Grade Pleomorphic Sarcoma of the Spine.2019Spine
  12. Establishment of a Nomogram-Based Model for Predicting the Prognostic Value of Inflammatory Biomarkers and Preoperative D-Dimer Level in Spinal Ewing's Sarcoma Family Tumors: A Retrospective Study of 83 Patients.2019World neurosurgery
  13. Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin signaling.2018Biochemical and biophysical research communications
  14. Heat shock transcription factor 1 promotes the proliferation, migration and invasion of osteosarcoma cells.2017Cell proliferation
  15. A support vector machine classifier for the prediction of osteosarcoma metastasis with high accuracy.2017International journal of molecular medicine
  16. Does rarity mean imparity? Biological characteristics of osteosarcoma cells originating from the spine.2017Journal of cancer research and clinical oncology
  17. Factors affecting survival outcomes of patients with non-metastatic Ewing's sarcoma family tumors in the spine: a retrospective analysis of 63 patients in a single center.2017Journal of neuro-oncology
  18. MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy.2017Scientific reports
  19. Parthenolide Induces Reactive Oxygen Species-Mediated Autophagic Cell Death in Human Osteosarcoma Cells.2016Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  20. Promotion of tumour proliferation, migration and invasion by miR-92b in targeting RECK in osteosarcoma.2016Clinical science (London, England : 1979)
  21. TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma.2016Journal of cancer research and clinical oncology
  22. Effects of RNA interference-mediated knockdown of livin and survivin using monomethoxypolyethylene glycol-chitosan nanoparticles in MG-63 osteosarcoma cells.2016Molecular medicine reports
  23. miR-146b-5p promotes invasion and metastasis contributing to chemoresistance in osteosarcoma by targeting zinc and ring finger 3.2016Oncology reports
  24. The predictive potential and oncogenic effects of HOXC8 expression on osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  25. P50-associated COX-2 extragenic RNA (PACER) overexpression promotes proliferation and metastasis of osteosarcoma cells by activating COX-2 gene.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 4 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 2220242025: 002025

21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. PEG-Ceramide Nanomicelles Induce Autophagy and Degrade Tau Proteins in N2a Cells.2020International journal of nanomedicine

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

15 hospitals in Shanghai for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 26 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.6%.

Papers led
26
2021–2025
Trials led
14
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 3320212022: 7720222023: 3320232024: 4420242025: 992025

16 hospitals in Shanghai for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
    Phase
    Early phase 1
    Started
    2024-06
    Registry
    NCT06407947

    Age 18 years to Not stated (registered criteria)

    Led by Changzheng HospitalShanghai

  2. Recruiting
    a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT06718270

    Age 18 years to Not stated (registered criteria)

    Led by Changzheng HospitalShanghai

  3. Recruiting
    KPD Consolidation After ASCT in NDMM Patients
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06879379

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Shanghai

  4. Recruiting
    To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
    Phase
    Early phase 1
    Started
    2023-07
    Registry
    NCT06045091

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  5. Recruiting
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    Phase
    Phase 4
    Started
    2022-03
    Registry
    NCT05201781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an

  6. Recruiting
    Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT05594797

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Wenzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRelapse & resistanceDiagnosis, MRD & riskDrug combinations
Departments in papersPathology / laboratory medicine
Papers it led26
  1. Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTAN2025Annals of hematologyRCTFree full text
  2. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.2025Annals of hematologyRCTFree full text
  3. Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.2025BMC medical genomicsFree full text
  4. Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1.2025CancerFree full text
  5. DEK facilitates bortezomib resistance of multiple myeloma by modulating ferroptosis.2025Clinical and experimental medicineFree full text
  6. Prognostic significance of hematological parameters and albumin in BCMA-targeted CAR-T therapy for multiple myeloma.2025Frontiers in immunologyFree full text
  7. Extracellular Ubiquitin Drives M2 Macrophage Polarization in Multiple Myeloma Through JAK1/STAT3-mediated Transcriptional Activation of CXCR4.2025Journal of cellular biochemistry
  8. CALR regulates the proliferation and drug sensitivity of multiple myeloma cells through the BCL2 signaling pathway.2025Molecular biology reports
  9. GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial.2025The Lancet. Haematology
  10. Interference with PLA2G16 promotes cell cycle arrest and apoptosis and inhibits the reprogramming of glucose metabolism in multiple myeloma cells by modulating the Hippo/YAP signaling pathway.2024Anti-cancer drugsFree full text
  11. Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.2024Clinical and experimental immunology
  12. A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma.2024Clinical cancer research : an official journal of the American Association for Cancer ResearchFree full text
  13. B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma.2024JAMA oncologyFree full text
  14. Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma.2023Blood cancer journalFree full text
  15. Identification and validation of a cellular senescence-related lncRNA signature for prognostic prediction in patients with multiple myeloma.2023Cell cycle (Georgetown, Tex.)Free full text
  16. Sensitive quantitative IgD assay increases progression-free survival prediction accuracy in IgD plasma cell myeloma.2023Leukemia
  17. Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.2022American journal of hematology
  18. CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status.2022American journal of hematology
  19. Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.2022BMC cancerFree full text
  20. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.2022BMC medicineFree full text
  21. Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.2022Clinical and translational medicineFree full text
  22. Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients.2022Journal of thrombosis and thrombolysis
  23. CircRNAs: novel therapeutic targets in multiple myeloma.2022Molecular biology reports
  24. Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma.2021HaematologicaFree full text
  25. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.2021International journal of hematology
  26. Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN).2021LeukemiaFree full text
Chinese-language papers (not in the count)6
  1. [BCMA chimeric antigen receptor T cells therapy re-treatment of a patient with recurrent/refractory IgD multiple myeloma: A case report and literature review].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [The efficacy and safety analysis of pomalidomide in the treatment of relapsed/refractory multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  3. [Interpretation of diagnosis of multiple myeloma in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].2022Zhonghua nei ke za zhi
  4. [Analysis of clinical characteristics and prognosis of non-secretory multiple myeloma].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  5. [A case-control study of multiple myeloma patients with central nervous system involvement].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  6. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status36
  1. Study of CT071 Injection in High Risk Newly Diagnosed Multiple MyelomaRecruitingNCT06407947Lead sponsorEarly phase 1Start 2024-06
  2. a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaRecruitingNCT06718270Lead sponsorEarly phase 1Start 2024-12
  3. Study of CT071 Injection in RRMM or PPCLActive, not recruitingNCT05838131Lead sponsorEarly phase 1Start 2023-04
  4. Study of FasT CAR-T GC012F Injection NDMM PatientsStatus unknownNCT05840107Lead sponsorEarly phase 1Start 2023-05
  5. BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT05376345Lead sponsorPhase 1Start 2022-09
  6. Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple MyelomaStatus unknownNCT05412329Lead sponsorPhase 1Start 2022-06
  7. BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple MyelomaStatus unknownNCT04617704Lead sponsorEarly phase 1Start 2021-12
  8. Study of FasT CAR-T GC012F Injection in High Risk TE NDMM PatientsStatus unknownNCT04935580Lead sponsorPhase 1/Phase 2Start 2021-06
  9. BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple MyelomaStatus unknownNCT04236011Lead sponsorEarly phase 1Start 2020-01
  10. Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple MyelomaStatus unknownNCT04122092Lead sponsorStart 2019-10
  11. A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple MyelomaCompletedNCT01852799Lead sponsorPhase 2Start 2012-12
  12. Selinexor in Combination With Immunomodulator (Thalidomide/Pomalidomide/Lenalidomide)in RRMMStatus unknownNCT04941937Lead (inferred)Phase 2Start 2022-01
  13. A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple MyelomaStatus unknownNCT04601935Lead (inferred)Phase 1Start 2020-10
  14. Efficacy Study of PAD and TAD in Newly Diagnosed Multiple MyelomaStatus unknownNCT01249690Lead (inferred)Phase 4Start 2010-06
  15. KPD Consolidation After ASCT in NDMM PatientsRecruitingNCT06879379Study sitePhase 2/Phase 3Start 2025-03
  16. To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCLRecruitingNCT06045091Study siteEarly phase 1Start 2023-07
  17. Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MMRecruitingNCT05594797Study sitePhase 2Start 2022-07
  18. A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Study sitePhase 4Start 2022-03
  19. To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MMActive, not recruitingNCT05302648Study siteEarly phase 1Start 2022-02
  20. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  21. A Study of Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04557098Study sitePhase 2Start 2020-09
  22. BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple MyelomaStatus unknownNCT03943472Study siteEarly phase 1Start 2019-07
  23. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT03758417Study sitePhase 2Start 2019-01
  24. Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple MyelomaStatus unknownNCT04003168Study sitePhase 1Start 2019-07
  25. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Study sitePhase 3Start 2019-01
  26. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  27. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  28. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  29. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  30. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03
  31. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  32. Ixazomib Rollover StudyCompletedNCT02924272Study sitePhase 2Start 2016-12
  33. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Study sitePhase 3Start 2015-04
  34. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07
  35. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Study sitePhase 2Start 2012-09
  36. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Study sitePhase 2Start 2010-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Shanghai for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

9 hospitals in Shanghai for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

17 hospitals in Shanghai for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Clinical diagnosis and management of cervical spondylotic amyotrophy].2017Zhonghua yi xue za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

15 hospitals in Shanghai for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 5 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.7%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025

26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 2 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 2.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

6 hospitals in Shanghai for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led2
  1. Dysfunction of Caveolae-Mediated Endocytic TβRI Degradation Results in Hypersensitivity of TGF-β/Smad Signaling in Osteogenesis Imperfecta.2023Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  2. Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta.2021BioMed research international
Earlier papers (2016–2020)3
  1. Efficacy of Bisphosphonates on Bone Mineral Density and Fracture Rate in Patients With Osteogenesis Imperfecta: A Systematic Review and Meta-analysis.2016American journal of therapeutics
  2. Response to Comment on Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta.2016Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  3. Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta.2016Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

17 hospitals in Shanghai for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

9 hospitals in Shanghai for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

海军军医大学第二附属医院(长征医院)

Changzheng Hospital

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Shanghai Changzheng Hospital; Second Affiliated Hospital of Naval Medical University; Changzheng Hospital of Naval Medicine University; Changzheng Hospital of the Navy Medical University; Zhabei Branch of Changzheng Hospital; Changzheng Hospital of Naval Medical University; Second Military Medical University/Changzheng Hospital; ChangZheng Hospital

Suggest a correctionDownload the data